Latest Morning Briefing Stories
Workers Overdose On The Job, And Employers Struggle To Respond
Despite the growing epidemic of Americans misusing opioids and overdosing on the job, many employers turn a blind eye to addiction within their workforce — ill-equipped or unwilling to confront an issue they are at a loss to handle.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
As States Try To Rein In Drug Spending, Feds Slap Down One Bold Medicaid Move
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren’t proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
New Medicare Advantage Tool To Lower Drug Prices Puts Crimp In Patients’ Choices
Federal officials are allowing the private insurance plans to use “step therapy” for drugs administered by doctors. In step therapy, patients must first use cheaper drugs to see if they work before receiving more expensive options.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Insurer To Purdue Pharma: We Won’t Pay For OxyContin Anymore
Embattled drugmaker Purdue Pharma defends OxyContin as some insurers are dropping the drug in favor of other abuse-deterrent opioid painkillers.
Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
El alto precio de la insulina lleva a que pacientes la racionen, a riesgo de muerte
El precio de la insulina en los Estados Unidos aumentó más del doble desde 2012. Eso pone a la hormona que salva vidas fuera del alcance de algunas personas con diabetes.
Insulin’s Steep Price Leads To Deadly Rationing
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn’t afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
States Looking To Tax Opioids Pin Hopes On November Elections
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
Giuliani’s Consulting Firm Helped Halt Purdue Opioid Investigation In Florida
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue’s marketing of OxyContin.
Legisladores presionan para proteger a los pacientes y llevarle la contra a Trump
Los legisladores de California jugaron ataque y defensa este año en el tema de salud, promulgando proyectos para ampliar el acceso a la vez que desafiando a las normas de Trump.
Lawmakers Push To Protect Patients And Counter Trump
California legislators approved some significant health care proposals in their rush to meet the Friday end-of-session deadline. They tackled controversial topics, such as making abortion pills available on college campuses, and adopted measures countering Trump administration attacks on the Affordable Care Act.
Podcast: KHN’s ‘What The Health?’ Ask Us Anything!
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico answer listeners’ questions about health policy and politics.
Podcast: KHN’s ‘What The Health?’ Opioids, EpiPens And Health Funding
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico discuss Senate action on health funding and opioid legislation, the state of the individual insurance market and consternation over expiration dates on EpiPens, the self-injected allergy remedy. Also, could an otter with asthma signal a potential public health crisis?
Rehabilitation Plus Rehab? Jails Dispense Drugs To Treat Inmates’ Addictions
Rather than go cold turkey, inmates increasingly have the option to take medication to help beat addiction to opioids and other substances. But some warn these substitute drugs serve as another crutch — and a costly one at that.
The Man Who Sold America On Vitamin D — And Profited In The Process
The doctor most responsible for turning the sunshine supplement into a billion-dollar juggernaut has received hundreds of thousands of dollars from the vitamin D industry, according to government records and interviews.
Purdue Pharma’s Sales Pitch Downplayed Risks Of Opioid Addiction
Through a widely circulated brochure and a videotape of testimonials, the maker of OxyContin stressed patients’ right to opioid treatment for pain.
